Berita Terbaru             -  Actemra® (Tocilizumab) and Risk of Hepatotoxicity            -  Buletin Berita MESO Volume 37, No 1 Edisi Juni 2019            -  Buletin Berita MESO Volume 37, No 1 Edisi Juni 2019            -  INFORMASI LANJUTAN (FOLLOW UP COMMUNICATION) UNTUK TENAGA KESEHATAN PROFESIONAL TENTANG TINDAK LANJUT ANGIOTENSIN II RECEPTOR BLOCKER (ARB)            -  INFORMASI LANJUTAN (FOLLOW UP COMMUNICATION) UNTUK TENAGA KESEHATAN PROFESIONAL TENTANG TINDAK LANJUT ANGIOTENSIN II RECEPTOR BLOCKER (ARB)

Safety Communication

As a form of responsibility of the pharmaceutical industry in monitoring the safety aspects of the drugs produced and marketed, PT Roche Indonesia  diseminate safety communication for healthcare professionals regarding the risk of hepatotoxicity associated with the use of Actemra® (Tocilizumab). Serious drug-induced liver injuries, including acute liver failure, hepatitis and jaundice, in some cases requiring liver transplant, have been observed with the administration of Actemra®. Although the frequency of serious hepatotoxicity is considered rare, caution should be exercised when considering initiation of Actemra® treatment in patients with ALT or AST above 1.5X ULN, patient with Rheumatoid Arthritis and Polyarticular Juvenile Idiopathic Arthritis. Please refer to the attached letter for details information.

 

Regards,

National Pharmacovigilance Center

National Agency of Drug and Food Control (NADFC)


Download : Final DHPC Actemra.rar
How do you think the content and appearance of this website?




logo dsras Email Rapid Alert System

Selamat email anda telah berlangganan untuk selalu mendapatkan informasi terkini mengenai keamanan obat yang beredar di Indonesia.

 

logo dsras Email Rapid Alert System

Anda ingin berhenti berlangganan untuk selalu mendapatkan informasi terkini mengenai keamanan obat yang beredar di Indonesia?